{"entity":{"id":"nct05261750","kind":"trial","name":"Autologous Dendritic Cells and Allogenic Dendritic Secretomes for Patients With Advanced Nasopharyngeal Cancer","aka":[],"tldr":"A phase 1/2 trial of Auto-DC (Autologous Dendritic Cell as Adjuvant Therapy) in nasopharyngeal carcinoma, run by PT. Prodia Stem Cell Indonesia, active and no longer recruiting.","summary":"Autologous Dendritic Cells and Allogenic Dendritic Secretomes for Patients With Advanced Nasopharyngeal Cancer is a phase 1/2 interventional study registered as NCT05261750 by PT. Prodia Stem Cell Indonesia, with 15 participants enrolled, started 2022-04-30 and due to reach its primary completion in 2026-02-28. Interventions recorded: Auto-DC (Autologous Dendritic Cell as Adjuvant Therapy) and Combination of Auto DC and Allo-Dendritic Cell-Secretome (Allogeneic Dendritic Cell-Secretome as Adjuvant Therapy).","status":"active","asOf":"2026-09-16","links":[{"label":"ClinicalTrials.gov NCT05261750","url":"https://clinicaltrials.gov/study/NCT05261750"}],"tags":["pipeline","ctgov-ingest"],"related":[],"cancers":["nasopharyngeal"],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"notes":[],"nct":"NCT05261750","phase":"1/2","setting":"Safety and Efficacy of Adjuvant Therapy of Autologous Dendritic Cells and Allogenic Dendritic Secretomes for Patients With Advanced Nasopharyngeal Cancer","sponsor":"PT. Prodia Stem Cell Indonesia","enrolled":15,"outcomes":[]},"route":"/trials/nct05261750/","neighbours":{"cancer":[{"id":"nasopharyngeal","kind":"cancer","name":"Nasopharyngeal carcinoma","route":"/cancers/nasopharyngeal/"}]}}